Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from Needham & Company LLC
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $24.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of 288.35% from […]
Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $24.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of 288.35% from […]
